Amylyx Pharmaceuticals IncNASDAQ:AMLX
- LAST PRICE1.8100
- TODAY'S CHANGE (%)-0.0900 (-4.7368%)
- Bid / Lots1.7900/ 2
- Ask / Lots1.8400/ 77
- Open / Previous Close1.9200 / 1.9000
- Day Range
- 52 Week Range
- Volume1,882,747
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AMLX |
|---|---|---|
| 09:32 ET | 17947 | 1.8893 |
| 09:34 ET | 6277 | 1.88 |
| 09:36 ET | 9545 | 1.8799 |
| 09:38 ET | 5614 | 1.89 |
| 09:39 ET | 9556 | 1.895 |
| 09:41 ET | 634 | 1.905 |
| 09:43 ET | 9754 | 1.92 |
| 09:45 ET | 1395 | 1.9212 |
| 09:48 ET | 12971 | 1.93 |
| 09:50 ET | 3099 | 1.9363 |
| 09:52 ET | 750 | 1.935 |
| 09:54 ET | 12868 | 1.945 |
| 09:56 ET | 15410 | 1.94 |
| 09:57 ET | 601 | 1.945 |
| 09:59 ET | 3775 | 1.95 |
| 10:01 ET | 3028 | 1.9524 |
| 10:03 ET | 726 | 1.95 |
| 10:06 ET | 1554 | 1.955 |
| 10:08 ET | 13158 | 1.965 |
| 10:10 ET | 66515 | 1.965 |
| 10:12 ET | 27333 | 1.94 |
| 10:14 ET | 20869 | 1.935 |
| 10:15 ET | 1653 | 1.94 |
| 10:17 ET | 5882 | 1.9417 |
| 10:19 ET | 400 | 1.9407 |
| 10:21 ET | 23854 | 1.9207 |
| 10:24 ET | 5201 | 1.925 |
| 10:26 ET | 650 | 1.928 |
| 10:28 ET | 1674 | 1.915 |
| 10:30 ET | 7467 | 1.91 |
| 10:32 ET | 1685 | 1.915 |
| 10:33 ET | 1200 | 1.915 |
| 10:35 ET | 1333 | 1.92 |
| 10:37 ET | 4647 | 1.925 |
| 10:39 ET | 3350 | 1.9275 |
| 10:42 ET | 503 | 1.92 |
| 10:44 ET | 1700 | 1.925 |
| 10:46 ET | 211 | 1.92 |
| 10:48 ET | 400 | 1.925 |
| 10:50 ET | 1636 | 1.92 |
| 10:51 ET | 901 | 1.9205 |
| 10:53 ET | 1291 | 1.93 |
| 10:55 ET | 300 | 1.925 |
| 10:57 ET | 17554 | 1.915 |
| 11:00 ET | 300 | 1.915 |
| 11:02 ET | 1300 | 1.915 |
| 11:04 ET | 1814 | 1.915 |
| 11:06 ET | 5787 | 1.925 |
| 11:08 ET | 300 | 1.9207 |
| 11:09 ET | 500 | 1.93 |
| 11:11 ET | 300 | 1.93 |
| 11:13 ET | 1806 | 1.925 |
| 11:15 ET | 1547 | 1.925 |
| 11:18 ET | 934 | 1.92 |
| 11:20 ET | 26622 | 1.9 |
| 11:22 ET | 870 | 1.9 |
| 11:24 ET | 807 | 1.905 |
| 11:26 ET | 877 | 1.905 |
| 11:27 ET | 5240 | 1.905 |
| 11:29 ET | 3726 | 1.905 |
| 11:31 ET | 1277 | 1.9 |
| 11:33 ET | 1400 | 1.905 |
| 11:36 ET | 1430 | 1.91 |
| 11:38 ET | 500 | 1.91 |
| 11:40 ET | 200 | 1.905 |
| 11:42 ET | 40319 | 1.91 |
| 11:44 ET | 300 | 1.915 |
| 11:45 ET | 719 | 1.915 |
| 11:47 ET | 8967 | 1.91 |
| 11:49 ET | 689 | 1.915 |
| 11:51 ET | 2298 | 1.9199 |
| 11:54 ET | 5317 | 1.915 |
| 11:56 ET | 100 | 1.91 |
| 11:58 ET | 100 | 1.91 |
| 12:00 ET | 2824 | 1.915 |
| 12:02 ET | 1680 | 1.91 |
| 12:03 ET | 920 | 1.915 |
| 12:05 ET | 2206 | 1.92 |
| 12:07 ET | 4735 | 1.915 |
| 12:09 ET | 774 | 1.915 |
| 12:12 ET | 500 | 1.915 |
| 12:14 ET | 400 | 1.915 |
| 12:16 ET | 1360 | 1.91 |
| 12:18 ET | 2645 | 1.915 |
| 12:20 ET | 3808 | 1.91 |
| 12:21 ET | 300 | 1.91 |
| 12:23 ET | 2088 | 1.915 |
| 12:25 ET | 1460 | 1.915 |
| 12:27 ET | 850 | 1.91 |
| 12:30 ET | 1636 | 1.915 |
| 12:32 ET | 600 | 1.9121 |
| 12:34 ET | 348 | 1.915 |
| 12:36 ET | 19776 | 1.885 |
| 12:38 ET | 1650 | 1.88 |
| 12:39 ET | 400 | 1.88 |
| 12:41 ET | 9007 | 1.875 |
| 12:43 ET | 3378 | 1.86 |
| 12:45 ET | 3970 | 1.86 |
| 12:48 ET | 1520 | 1.865 |
| 12:50 ET | 200 | 1.86 |
| 12:52 ET | 27070 | 1.855 |
| 12:54 ET | 8531 | 1.865 |
| 12:56 ET | 341 | 1.865 |
| 12:57 ET | 1100 | 1.8613 |
| 12:59 ET | 640 | 1.86 |
| 01:01 ET | 100 | 1.865 |
| 01:03 ET | 2193 | 1.865 |
| 01:06 ET | 300 | 1.86 |
| 01:08 ET | 500 | 1.865 |
| 01:10 ET | 1917 | 1.86 |
| 01:12 ET | 1148 | 1.86 |
| 01:14 ET | 900 | 1.86 |
| 01:15 ET | 200 | 1.86 |
| 01:17 ET | 2500 | 1.86 |
| 01:19 ET | 40947 | 1.865 |
| 01:21 ET | 2300 | 1.865 |
| 01:24 ET | 200 | 1.865 |
| 01:28 ET | 100 | 1.86 |
| 01:30 ET | 600 | 1.8632 |
| 01:32 ET | 320 | 1.86 |
| 01:33 ET | 857 | 1.86 |
| 01:35 ET | 4528 | 1.85 |
| 01:37 ET | 1110 | 1.85 |
| 01:39 ET | 1283 | 1.85 |
| 01:42 ET | 830 | 1.85 |
| 01:44 ET | 3133 | 1.853 |
| 01:46 ET | 3760 | 1.85 |
| 01:48 ET | 835 | 1.85 |
| 01:50 ET | 1190 | 1.85 |
| 01:51 ET | 1477 | 1.85 |
| 01:53 ET | 1106 | 1.8505 |
| 01:55 ET | 1640 | 1.85 |
| 01:57 ET | 854 | 1.85 |
| 02:00 ET | 14250 | 1.84 |
| 02:02 ET | 8012 | 1.845 |
| 02:04 ET | 2100 | 1.8499 |
| 02:06 ET | 6078 | 1.84 |
| 02:08 ET | 820 | 1.84 |
| 02:09 ET | 1411 | 1.84 |
| 02:11 ET | 26505 | 1.85 |
| 02:13 ET | 2983 | 1.86 |
| 02:15 ET | 1413 | 1.86 |
| 02:18 ET | 49407 | 1.9 |
| 02:20 ET | 100 | 1.9 |
| 02:22 ET | 1300 | 1.9 |
| 02:24 ET | 84267 | 1.885 |
| 02:26 ET | 800 | 1.885 |
| 02:27 ET | 1413 | 1.88 |
| 02:31 ET | 779 | 1.885 |
| 02:33 ET | 1531 | 1.88 |
| 02:36 ET | 30044 | 1.885 |
| 02:38 ET | 2864 | 1.88 |
| 02:40 ET | 1376 | 1.89 |
| 02:42 ET | 3404 | 1.885 |
| 02:44 ET | 3798 | 1.88 |
| 02:45 ET | 17906 | 1.875 |
| 02:47 ET | 930 | 1.87 |
| 02:49 ET | 10192 | 1.86 |
| 02:51 ET | 800 | 1.86 |
| 02:54 ET | 23054 | 1.85 |
| 02:56 ET | 967 | 1.85 |
| 02:58 ET | 8190 | 1.86 |
| 03:00 ET | 43583 | 1.855 |
| 03:02 ET | 1200 | 1.855 |
| 03:03 ET | 600 | 1.855 |
| 03:05 ET | 450 | 1.85 |
| 03:07 ET | 3600 | 1.855 |
| 03:09 ET | 1342 | 1.85 |
| 03:12 ET | 26167 | 1.84 |
| 03:14 ET | 1942 | 1.84 |
| 03:16 ET | 2884 | 1.845 |
| 03:18 ET | 6260 | 1.84 |
| 03:20 ET | 58149 | 1.845 |
| 03:21 ET | 75107 | 1.86 |
| 03:23 ET | 3295 | 1.85 |
| 03:25 ET | 522 | 1.855 |
| 03:27 ET | 820 | 1.855 |
| 03:30 ET | 320 | 1.86 |
| 03:32 ET | 20192 | 1.855 |
| 03:34 ET | 34920 | 1.85 |
| 03:36 ET | 11336 | 1.86 |
| 03:38 ET | 16582 | 1.86 |
| 03:39 ET | 5810 | 1.8582 |
| 03:41 ET | 31660 | 1.855 |
| 03:43 ET | 1026 | 1.85 |
| 03:45 ET | 1862 | 1.855 |
| 03:48 ET | 3271 | 1.85 |
| 03:50 ET | 4183 | 1.86 |
| 03:52 ET | 10340 | 1.85 |
| 03:54 ET | 34775 | 1.845 |
| 03:56 ET | 27944 | 1.82 |
| 03:57 ET | 14436 | 1.82 |
| 03:59 ET | 213657 | 1.81 |
Apr 25, 2024
Lifshitz Law PLLC Announces Investigations of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), Cassava Sciences, Inc. (NASDAQ:SAVA), GrafTech International Ltd. (NYSE:EAF), and Mobileye Global Inc. (NASDAQ:MBLY), from 10:52PM ET on Thursday Apr 25, 2024 by Dow Jones
10:52PM ET on Thursday Apr 25, 2024 by Dow Jones
Apr 16, 2024
Lifshitz Law PLLC Announces Investigations of Meta Platforms, Inc. (NASDAQ: META), Amplitude, Inc. (NASDAQ: AMPL), ON Semiconductor Corporation (NASDAQ: ON), and Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), from 10:01PM ET on Tuesday Apr 16, 2024 by Dow Jones
10:01PM ET on Tuesday Apr 16, 2024 by Dow Jones
Apr 15, 2024
Investigation Alert Amylyx, Hut 8, Xponential Fitness, and iRhythm Technologies: Submit Your Information Now to Johnson Fistel, LLP, from 11:21AM ET on Monday Apr 15, 2024 by Dow Jones
11:21AM ET on Monday Apr 15, 2024 by Dow Jones
Apr 11, 2024
DJ Amylyx Pharmaceuticals Is Maintained at Neutral by Baird, from 6:53AM ET on Thursday Apr 11, 2024 by Dow Jones
6:53AM ET on Thursday Apr 11, 2024 by Dow JonesDJ Amylyx Pharmaceuticals Price Target Maintained With a $8.00/Share by HC Wainwright & Co., from 6:39AM ET on Thursday Apr 11, 2024 by Dow Jones
6:39AM ET on Thursday Apr 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Amylyx Pharmaceuticals Inc | 128.8M | 2.6x | --- |
Organogenesis Holdings Inc | 324.0M | 63.9x | --- |
Amarin Corporation PLC | 360.2M | -6.4x | --- |
Coherus BioSciences Inc | 234.9M | -0.8x | --- |
CareDx Inc | 424.6M | -2.2x | --- |
Invitae Corp | 286.5K | 0.0x | --- |
Company Information
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate, AMX0035 (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS). RELYVRIO (also known as AMX0035), an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol is approved to treat ALS in adults in the United States. AMX0035 is a dual unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). Its development of antisense oligonucleotides (ASOs), including lead ASO AMX0114, which targets calpain-2 (CAPN2), a gene encoding calcium-dependent proteolytic enzyme which has been implicated in the pathogenesis of ALS and other neurodegenerative diseases.
Contact Information
- Headquarters
- 43 THORNDIKE STREETCAMBRIDGE, MA, United States 02141
- Phone
- 617-682-0917
- Fax
- 302-636-5454
Executives
- Chair of the Board of Directors
- George Milne
- Co-Chief Executive Officer, Director
- Joshua Cohen
- Co-Chief Executive Officer, Director
- Justin Klee
- Chief Financial Officer
- James Frates
- Chief Legal Officer and General Counsel
- Gina Mazzariello
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $128.8M |
|---|---|
Revenue (TTM) | $380.8M |
Shares Outstanding | 67.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $0.70 |
Book Value | $6.40 |
P/E Ratio | 2.6x |
Price/Sales (TTM) | 0.3 |
Price/Cash Flow (TTM) | 2.6x |
Operating Margin | 10.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
